Age and co-morbidity in cancer patients: a population-based approach.

摘要: There is now clear evidence that the prevalence of co-morbidity among older cancer patients high and (with comorbidity) are often treated less aggressively, which seems to have a negative influence on survival. However, would outcomes really improve if more were treated, according guidelines developed basis results in groups younger without co-morbidity? Would complications occur with If case, it possible develop special treatment regimens for adapt guidelines? It remains relevant study age toxicity from treatment, quality life prognosis unselected patients.